Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab
SW Ting, YC Chen, YH Huang - Clinical Drug Investigation, 2018 - Springer
Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …
The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C
HY Chiu, CH Chen, MS Wu, YP Cheng… - British Journal of …, 2013 - academic.oup.com
Background Ustekinumab, an interleukin (IL)‐12 and IL‐23 blocker, has emerged as a new
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …
[HTML][HTML] The use of ustekinumab in a patient with severe psoriasis and positive HBV serology
RB Steglich, LP Meneghello, AVE Carvalho… - Anais brasileiros de …, 2014 - SciELO Brasil
Psoriasis is a chronic inflammatory, immune-mediated disease that affects 1% to 2% of the
world's population. Immunobiological medications are prescribed for certain patients with …
world's population. Immunobiological medications are prescribed for certain patients with …
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre …
Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …
The safety of ustekinumab treatment in patients with moderate‐to‐severe psoriasis and latent tuberculosis infection
TF Tsai, V Ho, M Song, P Szapary, T Kato… - British Journal of …, 2012 - academic.oup.com
Background Ustekinumab is a monoclonal antibody that targets interleukin (IL)‐12/23 p40 to
treat psoriasis. The IL‐12 pathway is also important in regulating immunity to Mycobacterium …
treat psoriasis. The IL‐12 pathway is also important in regulating immunity to Mycobacterium …
Managing psoriasis in patients with HBV or HCV infection: practical considerations
S Piaserico, F Messina, FP Russo - American Journal of Clinical …, 2019 - Springer
Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …
[HTML][HTML] The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection
EJ Song, P Whitman, J Samsel - JAAD Case Reports, 2021 - Elsevier
While the majority of patients with psoriasis will be treated with topical agents, a significant
number will still require escalation to systemic therapy. The choice of systemic therapy will …
number will still require escalation to systemic therapy. The choice of systemic therapy will …
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature
Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …
Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis
Z Cao, C Carter, KL Wilson… - Journal of Dermatological …, 2015 - Taylor & Francis
Objectives: Ustekinumab is the most recently approved biologic for the treatment of
moderate-to-severe psoriasis. Real-world dosing patterns of ustekinumab are yet to be fully …
moderate-to-severe psoriasis. Real-world dosing patterns of ustekinumab are yet to be fully …
[HTML][HTML] Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of Hepatitis B or Hepatitis C infection
M Megna, C Patruno, MR Bongiorno… - Clinical Drug …, 2022 - Springer
Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …